|
Index | - | P/E | - | EPS (ttm) | -4.24 | Insider Own | 6.88% | Shs Outstand | 34.86M | Perf Week | -2.26% |
Market Cap | 99.74M | Forward P/E | - | EPS next Y | -1.50 | Insider Trans | 0.00% | Shs Float | 34.61M | Perf Month | -13.67% |
Income | - | PEG | - | EPS next Q | -0.47 | Inst Own | 71.70% | Short Float | 0.46% | Perf Quarter | -2.26% |
Sales | - | P/S | - | EPS this Y | -137.00% | Inst Trans | -5.13% | Short Ratio | 2.83 | Perf Half Y | -71.60% |
Book/sh | 2.94 | P/B | 0.88 | EPS next Y | 25.70% | ROA | - | Target Price | 16.33 | Perf Year | -73.71% |
Cash/sh | 2.40 | P/C | 1.08 | EPS next 5Y | 29.90% | ROE | - | 52W Range | 1.98 - 14.00 | Perf YTD | -59.78% |
Dividend | - | P/FCF | - | EPS past 5Y | - | ROI | - | 52W High | -81.50% | Beta | - |
Dividend % | - | Quick Ratio | 11.80 | Sales past 5Y | - | Gross Margin | - | 52W Low | 30.81% | ATR | 0.23 |
Employees | 83 | Current Ratio | 11.80 | Sales Q/Q | - | Oper. Margin | - | RSI (14) | 47.90 | Volatility | 6.15% 8.46% |
Optionable | No | Debt/Eq | 0.00 | EPS Q/Q | 26.30% | Profit Margin | - | Rel Volume | 0.01 | Prev Close | 2.54 |
Shortable | Yes | LT Debt/Eq | 0.00 | Earnings | - | Payout | - | Avg Volume | 56.35K | Price | 2.59 |
Recom | 1.00 | SMA20 | 0.49% | SMA50 | -10.19% | SMA200 | -54.18% | Volume | 445 | Change | 1.78% |
![]() |
|
![]() | ||||||||||||||||||||||||||||||||||||||
![]() | ||||||||||||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||||||||||||
![]() | ||||||||||||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||||||||||||
![]() | ||||||||||||||||||||||||||||||||||||||
Surrozen, Inc., a biotechnology company, discovers and develops drug candidates to selectively modulate the Wnt pathway for tissue repair and regeneration. It is developing tissue-specific antibodies with application across various disease areas, including diseases of the intestine, liver, retina, cornea, lung, kidney, cochlea, skin, pancreas, and central nervous system. Its products in pipeline include SZN-043 a tissue-specific R-spondin mimetic for the treatment of severe liver disease; and SZN-1326, a bi-specific full-length human antibody that directly modulates Wnt signaling in target tissue by binding to particular Frizzled and LRP receptors that are expressed in intestinal crypts. Surrozen, Inc. was founded in 2015 and is headquartered in South San Francisco, California. | ||||||||||||||||||||||||||||||||||||||
![]() | ||||||||||||||||||||||||||||||||||||||
![]() |
open in yahoo | open in reuters | open in marketwatch | open in google |
Upgrade your FINVIZ experience
Join thousands of traders who make more informed decisions with our premium features. Real-time quotes, advanced visualizations, backtesting, and much more.
Learn more about FINVIZ*Elite